Mapi Hits Milestone For Viatris-Partnered Long-Acting Glatiramer

More Than 600 Patients Now Dosed In Pivotal Phase III Trial

 
• By Dean Rudge
  
Anti-recessionary injection (vaccination) by hundred dollar denomination close up on a black background
Mapi recently received an additional $20m investment from partner Viatris • Source: Shutterstock

More from Value Added Medicines

More from Products